Studies showed patients treated with azithromycin or clarithromycin for any reason, in the prior three years, had a significant reduction in cardiac death and stroke; and patients treated with azithromycin for six months had a continued reduction in the rates of heart attack and stroke.
Alzheimer’s patients treated with doxycycline 200 mg. and rifampin 300 mg. demonstrated significantly less cognitive decline. No long-term study has examined patients consistently treated with macrolides, to determine if treatment decreases the risk of Alzheimer’s or limits cognitive decline.
The studies confirm diagnosis and treatment of an infectious cause in cardiovascular disease and Alzheimer’s can benefit patients with these chronic diseases, and patients who are at risk of developing these chronic diseases.
See “The Origin of Disease: The War Within”, Chapters 10, 11.